多靶点CAR-T细胞疗法在急性B淋巴细胞白血病中的应用  

Application of multi-targeted CAR-T cell therapy in B-cell acute lymphoblastic leukemia

作　　者：曹金金 杜娟 瞿姗娜 朱明宇 汪洋[1] 胡翰 刘滨磊[1,2] CAO Jinjin;DU Juan;QU Shanna;ZHU Mingyu;WANG Yang;HU Han;LIU Binlei(School of Life and Health Sciences,Hubei University of Technology,Wuhan 430068;Wuhan Binhui Biopharmaceutical Co.,Ltd.,Wuhan 436030,China)

机构地区：[1]湖北工业大学生命科学与健康工程学院,湖北武汉430068 [2]武汉滨会生物科技股份有限公司,湖北武汉436030

出　　处：《基础医学与临床》2025年第5期675-680,共6页Basic and Clinical Medicine

基　　金：国家自然科学基金青年科学基金(82001758)。

摘　　要：嵌合抗原受体T(CAR-T)细胞疗法作为一种新型细胞免疫疗法,在治疗恶性血液瘤尤其是急性B淋巴细胞白血病的临床上已经展现出较好的疗效。然而,单一靶点选择存在抗原丧失和免疫逃逸等问题,因此多靶点治疗策略逐渐受到关注。多靶点CAR-T是通过同时靶向多个肿瘤相关抗原,既能有效避免单一靶点导致的抗原逃逸问题,降低了复发风险,又有望提高治疗效果。本文主要介绍了多靶点CAR-T细胞疗法的结构类型以及治疗急性B淋巴细胞白血病的临床试验应用,期望在未来为治疗急性B淋巴细胞白血病提供参考。Chimeric antigen receptor-modified T(CAR-T)cell therapy,as a new type of cellular immunotherapy,has shown good clinical efficacy in the treatment of malignant hematological tumors,especially B-cell acute lymphoblastic leukemia.However,there are problems such as antigen loss and immune evasion in single-target selection,so multi-target therapy strategies are gradually gaining attention.Multi-target CAR-T can effectively avoid antigen escape caused by a single target by targeting multiple tumor-associated antigens at the same time,reduce the risk of recurrence,and is expected to improve the therapeutic effect.This paper primarily discusses the structural types of multi-target CAR-T cell therapy and its clinical trial applications in the treatment of B-cell acute lymphoblastic leukemia(B-ALL),aiming to provide future references for the treatment of B-ALL.

关 键 词：多靶点 CAR-T细胞疗法 急性B淋巴细胞白血病 脱靶效应 肿瘤相关抗原 

分 类 号：R739.6[医药卫生—肿瘤]